Lilly answers pollution charge with $338k; Obama: FDA needs update;

> Eli Lilly has settled with the federal government over charges of air pollution from an Indiana manufacturing plant, agreeing to pay a $337,500 penalty but admitting to none of the charges. Story

> President Obama has identified the FDA as an agency that ought to be modernized. Article

> The World Health Organization is rolling up its sleeves on the topic of counterfeit drugs, but some members see a red herring in intellectual property rights issues. News

> UK regulatory changes illustrate the legislative perspective on drugs and drugmakers: approved medicines are less commercial assets owned by the brand holders and more public health tools to be co-managed by the companies and regulators. Item

> Contract researcher Quintiles now has a $30 million stake in Samsung's move into the biosimilars business through its funding contribution to the construction of a $266 million factory. Article

> DHL Global Forwarding Life Sciences is upgrading the capabilities of its competence centers via training and accreditation as a Qualified Envirotainer Provider of temperature-controlled unit-load devices for pharma transport. Report

> The FDA and U.S. Customs and Border Protection are using predictive risk-based evaluation to screen for adulterated erectile dysfunction and other unauthorized supplements at U.S. borders. Story

> Oracle now supplies an integration tool that lets users combine the software giant's Pedigree and Serialization Manager with software for inventory, manufacturing and order management. Announcement

> Codexis has promoted David Anton to chief technology officer and senior VP, process development and manufacturing. Codexis release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.